ClinicalTrials.gg
RecruitingNCT05997667Updated Aug 18, 2023

Study on the Efficacy and Safety of Rechargeable Implantable DBS System in the Treatment of Parkinson's Disease

An interventional study of Rechargeable implantable deep brain stimulation system and Rechargeable implantable deep brain stimulation system in Parkinson Disease, sponsored by Lepu Medical Technology (Beijing) Co., Ltd.. Recruiting at 7 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Lepu Medical Technology (Beijing) Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
74th of 211
60 · median 47
Started
2023
with 29 others
No phase
115 of 279
57 open now
Primary completion
2025-01
later than 21 of 134 live
Registered
147th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 74th largest by planned enrollment of the 211 interventional ones that give a count, is one of 30 that started in 2023, is one of 115 with no phase, reaches primary completion later than 21 of the 134 other live ones, and was the 147th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to verify the efficacy and safety of rechargeable implantable deep brain stimulation (DBS) system for the treatment of advanced primary Parkinson's disease.

Read the detailed description

This study is a prospective, multicenter, randomized controlled superiority clinical study. According to the unified inclusion and exclusion criteria, 60 eligible subjects are enrolled in this clinical trial. All subjects are implanted with bilateral deep brain stimulation leads, and are randomly assigned to the experimental group or control group in a 1:1 ratio. Within one month after surgery, the DBS system of experimental group is activated and the stimulation parameters are modulated, whereas the control group is not activated. The primary endpoint is the change in motor examination scores evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (MDS-UPDRS-III) in "med off" state at 3 months after surgery, compared to the baseline. After primary endpoint evaluation, both groups receive treatment with activated DBS system. The efficacy in med off/stim on and med on/stim on state and the safety are evaluated at 6 months after surgery.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Rechargeable implantable deep brain stimulation (DBS) system
  • Parkinson's disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years old, male or female;.
  2. Primary PD (according to the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for primary PD or Chinese diagnostic criteria for primary PD), with a duration of PD ≥ 4 years, and the improvement rate after an acute levodopa challenge test ≥ 30%; or primary PD, mainly characterized by tremor, the improvement of tremor by standardized drug treatment is not satisfactory and tremor is severe, which affects the patients' quality of life, after evaluation, duration can be relaxed to 3 years, the improvement rate of acute levodopa challenge test can be\<30%.
  3. The use of levodopa once had good effects, but currently cannot satisfactorily control symptoms (significant decrease in efficacy or occurrence of fluctuations in motor function or motor dysfunction), which affects quality of life.
  4. Good compliance, patients and their families have the willingness to participate in the clinical trial of "bilateral implantation surgery of nervous stimulation system", voluntarily participate in this trial and sign form, patients can follow up regularly, and can accurately complete of assessment items, or the family members, guardians, or caregivers may assist the patients.

Exclusion criteria

Exclusion Criteria:

  1. Severe cognitive impairment ( score: illiterate\<17, elementary school\<20, junior high school or above\<24), poor compliance due to dementia, and/or inability to sign form
  2. Patients with a history of severe mental illness and a Hamilton Depression Scale (HAMD) score>24
  3. Seizure history in the last 1 year
  4. Patients with severe heart, liver and kidney diseases, severe hypertension and severe orthostatic hypotension that affect their health status.
  5. Patients with severe diabetes or serious cardiovascular and cerebrovascular diseases that affect their health status
  6. Confirmed malignant tumor
  7. Patients with surgical (e.g., the presence of active implants (whether turned on or not), or the presence of non-active implants that may affect the deep brain stimulation system, stereotactic nucleus lesioning, etc.), or other surgical procedures within six months that the researchers believe have an impact on this trial, or other neurosurgery contraindications
  8. Patients who have suffered a previous cranial neurological injury
  9. Women who are pregnant or preparing for pregnancy
  10. Patients with severe alcohol dependence and drug abuse
  11. Patients who received electric shock therapy within 30 days before surgery
  12. Patients who are abnormally sensitive to temperature or who are allergic to heat
  13. Subjects who are currently participating in other clinical trials or have participated in other clinical studies that have not reached the primary endpoint within three months.
  14. Patients who are not suitable to participate in this clinical study in the opinion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    experimental group

    Subjects in this arm will receive stimulation of DBS system within 1 month after surgery.

    Device: Rechargeable implantable deep brain stimulation system

  • Other
    control group

    Subjects in this arm will receive stimulation of DBS system at 3 months after surgery.

    Device: Rechargeable implantable deep brain stimulation system

Interventions

  • DeviceRechargeable implantable deep brain stimulation system

    The DBS system will be implanted in subjects in both study arms. Subjects in experimental group will receive stimulation of DBS system within 1 month after surgery.

  • DeviceRechargeable implantable deep brain stimulation system

    The DBS system will be implanted in subjects in both study arms. Subjects in control group will receive stimulation of DBS system at 3 months after surgery.

06

What researchers measure

Primary outcomes

  1. Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅲ in "med off" state relative to baseline

    MDS-UPDRS Part Ⅲ (MDS-UPDRS-Ⅲ) scores range from 0 to 132, higher scores mean a worse outcome.

    Time frame: 3 months after surgery

Secondary outcomes

  1. Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅲ in "med on" state relative to baseline

    MDS-UPDRS Part Ⅲ (MDS-UPDRS-Ⅲ) scores range from 0 to 132, higher scores mean a worse outcome.

    Time frame: 3 months after surgery

  2. Change in motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅱ relative to baseline

    MDS-UPDRS Part Ⅱ (MDS-UPDRS-Ⅱ) scores range from 0 to 52, higher scores mean a worse outcome.

    Time frame: 3 and 6 months after surgery

  3. Change in non-motor experiences of daily living score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅰ relative to baseline

    MDS-UPDRS Part Ⅰ (MDS-UPDRS-Ⅰ) scores range from 0 to 52, higher scores mean a worse outcome.

    Time frame: 3 and 6 months after surgery

  4. Change in motor complications score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅳ relative to baseline

    MDS-UPDRS Part Ⅳ (MDS-UPDRS-Ⅳ) scores range from 0 to 24, higher scores mean a worse outcome.

    Time frame: 3 and 6 months after surgery

  5. Change in "ON" time and "OFF" time relative to the baseline

    Time frame: 3 and 6 months after surgery

  6. Change in motor examination score evaluated using the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part Ⅲ with stimulation in "med on" and "med off" states relative to baseline

    MDS-UPDRS Part Ⅲ (MDS-UPDRS-Ⅲ) scores range from 0 to 132, higher scores mean a worse outcome.

    Time frame: 6 months after surgery

  7. Change in daily levodopa equivalent dose relative to baseline

    Time frame: 3 and 6 months after surgery

  8. Change in the Parkinson's Disease Questionnaire (PDQ-39) score relative to baseline

    The Parkinson's Disease Questionnaire (PDQ-39) is a 39-item questionnaire designed to measure the specific impact of PD on quality of life. Scores range from 0 to 156, higher scores mean a worse outcome.

    Time frame: 6 months after surgery

  9. Evaluation of equipment operational performance

    The operational performance of the equipment is evaluated as excellent, good, or poor.

    Time frame: Within surgery, 1 month and 3 months after surgery

  10. Incidence of adverse events

    Time frame: up to 6 months after surgery

07

Study locations

1 of 7 sites recruiting
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing 100053, China
    Recruiting
    • Yuqing Zhang · Contact
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350004, China
    Not yet recruiting
    • Lianghong Yu · Contact
  • ZhuJiang Hospital of Southern Medical University
    Guangzhou, Guangdong 510260, China
    Not yet recruiting
    • Shizhong Zhang · Contact
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
    Not yet recruiting
    • Baohui Liu · Contact
  • The Second Affiliated Hospital of Air Force Medical University
    Xi'an, Shaanxi 524001, China
    Not yet recruiting
    • Xuelian Wang · Contact
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610044, China
    Not yet recruiting
    • Huifang Shang · Contact
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
    Not yet recruiting
    • Junming Zhu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2025, 18 months after the start.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 18, 2023
StartActual
Jul 20, 2023
Primary completionEst.
Jan 20, 2025
CompletionEst.
Jul 20, 2025
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05997667
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Jul 20, 2023
Primary completion
Jan 20, 2025 (estimated)
Completion
Jul 20, 2025 (estimated)
Last update
Aug 18, 2023

Study contacts

Ting Zhang
Contact
ting_zhang@lepumedical.com
+86-010-80120666

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion